Table 1.
Patient/Donor characteristics, complications and outcome (n=131)
| PATIENT | |
| Age at SCT in years (median) | 13–69 (46) |
| Sex of patients (m/f) | 83/48 |
| CMV positive | 75 (58%) |
| DONOR | |
| Sex of donors (m/f) | 90/41 |
| CMV positive | 73 (56%) |
| Matched/Mismatched | 107/24 |
| Related/Unrelated | 51/80 |
| DISEASE | |
| AML | 35 (27%) |
| ALL | 16 (12%) |
| Lymphoma | 11 (8%) |
| Multiple Myeloma | 20 (15%) |
| CML | 26 (20%) |
| Myelodysplastic Syndrome | 10 (8%) |
| Others | 13 (10%) |
| TYPE OF TRANSPLANT | |
| PBSC | 109 (83%) |
| BMT | 22 (17%) |
| CONDITIONING REGIMENS | |
| Bu/Cy+/−VP16 | 50 (38%) |
| TBI/Cy/VP16 | 19 (14%) |
| RIC | 62 (48%) |
| ENGRAFTMENT | |
| Leukocyte (≥ 1.0 ×109/L) | 6–26 days (mean 15) |
| Lymphocyte (×106/ml) | 20–3340 (mean 1008) |
| NK cells (×106/ml) | 8–858 (mean 239) |
| ACUTE GVHD | |
| Grade 0–I | 82 (63%) |
| Grade II–IV | 49 (37%) |
| Grade III–IV | 29 (22%) |
| INFECTIONS | |
| Definite sepsis | 50 (38%) |
| Clinical sepsis | 56 (43%) |
| Pneumonia | 76 (58%) |
| Fungal | 46 (35%) |
| Bacterial | 17 (13%) |
| Atypical | 8 (6%) |
| Viral | 5 (4%) |
| CMV infection/reactivation | |
| Yes | 46 (35%) |
| No | 85 (65%) |
| VZV/HSV infection/reactivation | |
| Yes | 33 (25%) |
| No | 98 (75%) |
| DEATH AND CAUSE | n=62 (47%) |
| Infection | 23 (17.5%) |
| TRM | 37 (28%) |
| Relapse | 20 |
| GvHD | 8 |
| GvHD with infection | 6 |
| Toxicity | 3 |
| Other | 2 (1.5%) |
PBCST, peripheral blood stem cell transplantation; BMT, bone marrow transplantation; NK cells, natural killer cells; Bu, Busulfan; Cy cyclophophamide; VP16, Etoposide; TBI, total body irradiation; RIC, reduced intensification conditioning